Shares of LENZ Therapeutics (LENZ) fell ~26% on Friday, a move TD Cowen attributed to investor worries over an adverse event reported on a federal database about the company’s newly launched eye ...

LENZ Therapeutics is rated HOLD as VIZZ’s commercial potential is highly dependent on uncertain consumer behavior, not medical necessity. LENZ’s current valuation reflects a base-case scenario where ...

Evert “Eef” Schimmelpennink is a busy guy. He’s the president and CEO of Lenz Therapeutics, a biopharmaceutical company in Solana Beach that recently rolled out a new product to treat the millions of ...

Jeffrey Lenz, 53, of Noblesville, Indiana, passed away peacefully on October 31, 2025, surrounded by his loved ones, following a brave battle with a glioblastoma brain tumor. He is survived by his ...

The price trend for LENZ Therapeutics, Inc. (LENZ) has been bearish lately and the stock has lost 6.3% over the past week. However, the formation of a hammer chart pattern in its last trading session ...

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ...

LENZ Therapeutics, Inc. (LENZ) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

A stretch of Montgomery County highway in the hometown of Army Specialist Joey Lenz now carries the name of the late soldier, forever paying tribute to his military service and legacy of kindness.

Caroline Lenz McClure passed away peacefully in Stockton on September 8, 2025. Caroline was a Stocktonian and member of a pioneer agricultural family. She was the daughter of Howard Oliver Lenz and ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past efforts by other drug developers have mostly been unsuccessful. The ...

Vizz, an aceclidine-based eye drop, is FDA-approved for presbyopia, enhancing near vision without myopic shifts. Successful Phase III trials showed Vizz's efficacy and safety, with near vision ...

Lenz Therapeutics is a clinical-stage biotech aiming to reshape vision correction for presbyopia, an age-related loss of near vision affecting people over forty. Its lead product, LNZ100, is a ...